Latest news with #UnitedStatesPrivateSecuritiesLitigationReformActof1995
Yahoo
13 hours ago
- Business
- Yahoo
EXL announces $125 million accelerated share repurchase program
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a global data and AI company, today announced that, as part of its capital allocation program, it has entered into an accelerated share repurchase agreement (the 'ASR') with Citibank, N.A. to repurchase $125 million of the company's common stock. Chairman and Chief Executive Officer Rohit Kapoor said, 'The successful execution of our data- and AI-led strategy has positioned EXL as an industry leader in embedding AI in the workflow to significantly enhance operational efficiencies, improve customer service and deliver improved business outcomes for our clients. The ASR reflects confidence in our ability to continue to deliver superior value to our clients, enabling us to sustain our double-digit growth momentum while maximizing stockholder value.' Under the ASR, the company will pay an aggregate amount of $125 million to Citibank for an initial number of shares of the company's common stock at the beginning of the transaction. The company plans to fund the repurchase with available cash on hand and/or borrowing from its credit facility. The ultimate number of shares of common stock that the company will repurchase under the ASR Agreement will be based on the average of the daily volume-weighted average prices of the common stock during the term of the ASR, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR. The ASR is a part of the company's existing $500 million stock repurchase program. About ExlService Holdings, Inc. EXL (NASDAQ: EXLS) is a global data and artificial intelligence ("AI") company that offers services and solutions to reinvent client business models, drive better outcomes and unlock growth with speed. EXL harnesses the power of data, AI, and deep industry knowledge to transform businesses, including the world's leading corporations in industries including insurance, healthcare, banking and financial services, media and retail, among others. EXL was founded in 1999 with the core values of innovation, collaboration, excellence, integrity and respect. We are headquartered in New York and have more than 61,000 employees spanning six continents. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to EXL's operations and business environment, all of which are difficult to predict and many of which are beyond EXL's control. Forward-looking statements include information concerning EXL's possible or assumed future results of operations, including descriptions of its business strategy. These statements may include words such as 'may,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'intend,' 'plan,' 'estimate' or similar expressions. These statements are based on assumptions that we have made in light of management's experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although EXL believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect EXL's actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors, which include our ability to maintain and grow client demand, our ability to hire and retain sufficiently trained employees, and our ability to accurately estimate and/or manage costs, rising interest rates, rising inflation and recessionary economic trends, are discussed in more detail in EXL's filings with the Securities and Exchange Commission, including EXL's Annual Report on Form 10-K. You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or how they may affect EXL. EXL has no obligation to update any forward-looking statements after the date hereof, except as required by applicable law. Contacts:Investor RelationsJohn KristoffVice President, Investor Relations+1 212 209 4613ir@ Media - USKeith LittleAssistant Vice President, Media Relations+1 703 598 l'accesso per consultare il tuo portafoglio
Business Wire
5 days ago
- Business
- Business Wire
OPAL Fuels Announces Second Quarter 2025 Earnings Release Date and Conference Call
WHITE PLAINS, N.Y.--(BUSINESS WIRE)-- OPAL Fuels Inc. A listen-only connection to the investor presentation will be accessible at Investors can also listen to a webcast of the presentation on the company's Investor Relations website at About OPAL Fuels Inc. OPAL Fuels Inc. (Nasdaq: OPAL) is a leader in the capture and conversion of biogas into low carbon intensity RNG and renewable electricity. OPAL Fuels is also a leader in the marketing and distribution of RNG to heavy duty trucking and other hard to de-carbonize industrial sectors. For additional information, and to learn more about OPAL Fuels and how it is leading the effort to capture North America's naturally occurring methane and decarbonize the economy, please visit Forward-Looking Statements Certain statements in this communication may be considered forward-looking statements within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or OPAL Fuels' (the 'Company's') future financial or other performance metrics. In some cases, you can identify forward-looking statements by terminology such as 'believe,' 'may,' 'will,' 'potentially,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'could,' 'would,' 'project,' 'target,' 'plan,' 'expect,' or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, as the case may be, are inherently uncertain and subject to material change. Factors that may cause actual results to differ materially from current expectations include various factors beyond management's control, including, but not limited to, general economic conditions and other risks, uncertainties and factors set forth in the sections entitled 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q, and other filings it makes with the Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. Disclaimer This communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy, any securities, nor shall there be any sale, issuance or transfer or securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Globe and Mail
5 days ago
- Business
- Globe and Mail
OPAL Fuels Announces Second Quarter 2025 Earnings Release Date and Conference Call
OPAL Fuels Inc. (Nasdaq: OPAL) announced that it will release its earnings results for the second quarter ended June 30, 2025, after market close on Thursday, August 7, 2025. A conference call will take place on Friday, August 8, 2025 at 11:00 a.m. Eastern Time. A listen-only connection to the investor presentation will be accessible at Investors can also listen to a webcast of the presentation on the company's Investor Relations website at About OPAL Fuels Inc. OPAL Fuels Inc. (Nasdaq: OPAL) is a leader in the capture and conversion of biogas into low carbon intensity RNG and renewable electricity. OPAL Fuels is also a leader in the marketing and distribution of RNG to heavy duty trucking and other hard to de-carbonize industrial sectors. For additional information, and to learn more about OPAL Fuels and how it is leading the effort to capture North America's naturally occurring methane and decarbonize the economy, please visit Forward-Looking Statements Certain statements in this communication may be considered forward-looking statements within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or OPAL Fuels' (the 'Company's') future financial or other performance metrics. In some cases, you can identify forward-looking statements by terminology such as 'believe,' 'may,' 'will,' 'potentially,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'could,' 'would,' 'project,' 'target,' 'plan,' 'expect,' or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, as the case may be, are inherently uncertain and subject to material change. Factors that may cause actual results to differ materially from current expectations include various factors beyond management's control, including, but not limited to, general economic conditions and other risks, uncertainties and factors set forth in the sections entitled 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q, and other filings it makes with the Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. Disclaimer This communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy, any securities, nor shall there be any sale, issuance or transfer or securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Business Upturn
15-07-2025
- Business
- Business Upturn
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. ('Perspective' or the 'Company') (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 before the market opens. The press release will be available on the newsroom section of the Company's website at About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This 'theranostic' approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor Statement This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its 'theranostic' approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading 'Risk Factors' in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the 'SEC'), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFA [email protected]
Business Wire
14-07-2025
- Business
- Business Wire
VSee New AI Doctor Notes Reduces Documentation Time 93% – Transforming Virtual Emergency Care for Tele911
SAN JOSE, Calif.--(BUSINESS WIRE)-- VSee Health, Inc. (Nasdaq: VSEE) a leading provider of secure digital health solutions, today announced the launch of its new AI doctor notes, one of the solutions in its AI solutions suite. VSee's AI Doctor Notes…has drastically reduced Tele911 physician's charting time by 93% from 15 minutes per visit to under 1 minute. VSee has partnered with Tele911, the largest national telemedicine emergency room diversion service, to integrate VSee's AI Doctor Notes into its virtual emergency care workflow. Emergency medicine demands rapid decision-making and high patient throughput. The integration has drastically reduced Tele911 physician's charting time by 93% from 15 minutes per visit to under 1 minute, potentially increasing physician visit capacity. This new VSee AI solution automatically transcribes visits and generates structured SOAP notes with ICD codes in two clicks, allowing Tele911 physicians to reclaim valuable time. Now, instead of manual documentation, clinicians can focus on patient care. Dr. Ramone Lizardo, MD, CEO of Tele911 states "VSee's AI Doctor Notes integration has been a game-changer for our physicians. As the nation's leading virtual ER from 911 calls, demand is high and efficiency is critical. With two clicks it allows our physicians to eliminate documentation busywork, so they can devote their full attention to patients and to improving care delivery at scale." Dr. Milton Chen, PhD, CEO of VSee adds: "Our AI SOAP notes isn't just about speed—it's about restoring the human connection in medicine. Tele911's adoption proves its transformative potential in high-acuity telemedicine." VSee's AI-powered documentation solution is available both as an integrated feature in the VSee digital health platform or as a stand alone solution that can be used side-by-side with any EHR. It presents a compelling opportunity for hospitals, clinics, and investors looking to enhance clinical efficiency and scalability. Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Certain of these forward-looking statements can be identified by the use of words such as 'believes,' 'expects, 'intends,' 'plans,' 'estimates,' 'assumes,' 'may,' 'should,' 'will,' 'seeks,' or other similar expressions. These statements are based on current expectations on the date of this press release and involve a number of risks and uncertainties that may cause actual results to differ significantly, including those risks set forth in the Company's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q and other documents filed with the SEC. Copies of such filings are available on the SEC's website at The Company does not assume any obligation to update or revise any such forward- looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to rely on forward-looking statements. About VSee Health VSee Health (Nasdaq: VSEE) is a rapidly growing leader in AI-powered telehealth, redefining the $787 billion digital healthcare market with its modular, no-code/low-code platform. Trusted by 1,000+ clients, including NASA, the U.S. Department of Health and Human Services, McKesson, DaVita, and the entire nation of Qatar, VSee Health provides foundational infrastructure for digital healthcare and delivers turnkey solutions to optimize healthcare operations while increasing billable patient visits and provider efficiency. Visit About Tele911 Tele911 Inc. is a healthcare technology company delivering telemedicine and patient navigation solutions tailored to the emergency medical services sector. The company was founded by leaders in emergency medicine and EMS, whose mission is to improve patients' lives and expand access to care, while reducing unnecessary healthcare costs and strain on providers. Tele911's telehealth platform provides integrated, intuitive, user-friendly clinical workflows. This enables more effective, efficient patient triage, care delivery, reporting and follow up to meet the needs of fire departments, EMS agencies, health systems, and local and national payer and risk-bearing organizations. For more information, visit
